At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease.
The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for:
› Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression.
› Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.
The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for:
› Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression.
› Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.
Location: United States, Massachusetts, Newburyport
Employees: 11-50
Total raised: $12M
Founded date: 2018
Investors 6
| Date | Name | Website |
| - | Dolby Fami... | dolbyventu... |
| - | Flucas Ven... | flucasvc.c... |
| - | Quark Vent... | quarkventu... |
| - | Tachyon Ve... | tachyon.vc |
| - | VU Venture... | vuventurep... |
| - | Bioverge | ventures.b... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.02.2020 | Series A | $10M | - |
| 14.03.2019 | Seed | $2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 04.09.2024 | EnClear Therapies Secures Additional Funding | EnClear Therapies, a Cambridge, MA-based early-stage neurotechnology company, raised additional funding. Backers included Brain Tumor Investment Fund and the Sontag Innovation Fund and existing investors such as Amgen Ventures, Founders Fun... |
| 21.02.2020 | Life Sciences Company EnClear Therapies Raises $10 Million | EnClear Therapies — a life sciences company developing device-based therapies for the treatment of neurodegenerative disease — announced it has raised $10 million in Series A EnClear Therapies — a life sciences company developing device-bas... |
| 19.02.2020 | EnClear Therapies Raises $10M in Series A Financing | EnClear Therapies, a Cambridge, Mass.-based life sciences company developing device-based therapies for the treatment of neurodegenerative disease, raised $10m in Series A financing. The round was led by 20/20 HealthCare Partners with parti... |
| 19.02.2020 | EnClear Therapies Announces $10M Series A Financing | - |
| 19.02.2020 | Daily funding roundup - February 19th, 2020 | Croquet raised $2.7M; BluBracket closed $6.5M; UltraSense Systems landed $20; Maven picks up $45M Croquet: Croquet is a game and app development platform for AR and 5G. Croquet has raised $2.7 million in seed funding, including $2 million f... |
| 19.02.2020 | EnClear Therapies Announces $10M Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today announced a $10 million Series A financing led by 20/20 HealthCare Partner... |
| 26.08.2019 | Presight Capital raises $80M fund to connect US startups with Europe | Presight Capital, the international venture arm of Apeiron Investment Group, is announcing that it’s closed its first fund of $80 million. Apeiron is the family office of German entrepreneur Christian Angermayer (pictured above), who previo... |
| 25.04.2019 | Enclear Therapies wins novel device challenge | EnClear Therapies’ system designed to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases was one of five first-place winners of the Massachusetts Life Sciences Center (M2D2) $200K Challenge. Cambridge, Mass.-base... |
| 14.03.2019 | EnClear Therapies Raises $2M in Seed Funding | EnClear Therapies, a Cambridge, MA-based biotechnology company developing device-based therapies for the treatment of neurodegenerative disease, secured approximately $2m in seed funding. Backers included Thiel Capital, Bioverge, Sanford Bi... |
| - | EnClear Therapies | “Home | EnClear Therapies” |